{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:10:15Z","timestamp":1790003415359,"version":"4.0.1"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.phrs.2024.107465","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T18:07:17Z","timestamp":1729274837000},"page":"107465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Targeted and cytotoxic inhibitors used in the treatment of lung cancers"],"prefix":"10.1016","volume":"209","author":[{"given":"Robert","family":"Roskoski Jr.","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2024.107465_bib1","series-title":"The MD Anderson Manual of Medical Oncology, fourth ed.","first-page":"495","article-title":"Non-small cell lung cancer","author":"Altan","year":"2022"},{"key":"10.1016\/j.phrs.2024.107465_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2024.107465_bib3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.35128","article-title":"Lung cancer statistics, 2023","volume":"130","author":"Kratzer","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2024.107465_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2024.107465_bib5","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.3390\/cancers16162882","article-title":"The genetic analysis and clinical therapy in lung cancer: current advances and future directions","volume":"16","author":"Rina","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2024.107465_bib6","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.3390\/jcm11061500","article-title":"Comprehensive characterization of human lung large cell carcinoma identifies transcriptomic signatures with potential implications in response to immunotherapy","volume":"11","author":"Ramos-Paradas","year":"2022","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.phrs.2024.107465_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, Version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.phrs.2024.107465_bib8","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2024.107465_bib9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/312513a0","article-title":"The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen","volume":"312","author":"Schechter","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107465_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107465_bib11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: structure and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107465_bib12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107465_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2024.107465_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107465_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107465_bib16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat. Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.phrs.2024.107465_bib17","doi-asserted-by":"crossref","first-page":"iii4","DOI":"10.1093\/annonc\/mdw301","article-title":"The role of the ALK receptor in cancer biology","volume":"27","author":"Hallberg","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib18","article-title":"A literature review of a meta-analysis of BRAF mutations in non-small cell lung cancer","volume":"103","author":"Chimbangu","year":"2024","journal-title":"Med. (Baltim.)"},{"key":"10.1016\/j.phrs.2024.107465_bib19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF protein-serine\/threonine kinases: structure and regulation","volume":"399","author":"Roskoski","year":"2010","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2024.107465_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107465_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107465_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107465_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107465_bib24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107465_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2024.101133","article-title":"ROS1-rearranged non-small cell lung cancer: understanding biology and optimizing management in the era of new approvals","volume":"53","author":"Myall","year":"2024","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.phrs.2024.107465_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107465_bib27","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.3390\/cancers16162877","article-title":"Non-small-cell lung cancers (NSCLCs) harboring RET gene fusion, from their discovery to the advent of new selective potent RET inhibitors: \"shadows and fogs\"","volume":"16","author":"Spitaleri","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2024.107465_bib28","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/17460441.2013.813015","article-title":"The preclinical profile of crizotinib in the treatment of non-small cell lung cancer and other neoplastic disorders","volume":"8","author":"Roskoski","year":"2013","journal-title":"Expert Opin. Drug Dis."},{"key":"10.1016\/j.phrs.2024.107465_bib29","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.phrs.2024.107465_bib30","doi-asserted-by":"crossref","first-page":"9101","DOI":"10.3390\/ijms25169101","article-title":"Unveiling the role of HGF\/c-Met signaling in non-small cell lung cancer tumor microenvironment","volume":"25","author":"Yao","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2024.107465_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11864-020-0723-5","article-title":"Management of non-small cell lung cancer patients with MET exon 14 skipping mutations","volume":"21","author":"Huang","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102733","article-title":"NTRK gene fusion testing and management in lung cancer","volume":"127","author":"Repetto","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2024.107465_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105806","article-title":"Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS","volume":"172","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107465_bib34","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.3390\/cancers15061635","article-title":"Treatment strategies for KRAS-mutated non-small-cell lung cancer","volume":"15","author":"O'Sullivan","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2024.107465_bib35","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3390\/cancers16132350","article-title":"Evolving precision first-line systemic treatment for patients with unresectable non-small cell lung cancer","volume":"16","author":"Li","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2024.107465_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2024.101106","article-title":"Current perspectives of KRAS in non-small cell lung cancer","volume":"51","author":"Harris","year":"2024","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.phrs.2024.107465_bib37","doi-asserted-by":"crossref","first-page":"9759","DOI":"10.1021\/acs.jmedchem.4c00978","article-title":"Discovery of potent and selective covalent inhibitors of HER2WT and HER2YVMA","volume":"67","author":"Hicken","year":"2024","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2024.107465_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100490","article-title":"Clinicopathologic and molecular characteristics of HER2 (ERBB2)-altered non-small cell lung cancer: implications for precision medicine","volume":"37","author":"Lee","year":"2024","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.phrs.2024.107465_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101480","article-title":"Emerging concepts in PD-1 checkpoint biology","volume":"52","author":"Pauken","year":"2021","journal-title":"Semin Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107465_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib41","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jtho.2015.10.008","volume":"11","author":"Nicholson","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib42","unstructured":"Morgensztern D., Detterbeck F.C., Drilon A., Goldberg S.B., Park H.S., Politi K., Schalper K.A., Tanoue, L.T., Herbst R.S. Non-small cell lung cancer. in DeVita VT Jr, Lawrence TS, Rosenberg SA (Eds.), Cancer Principles and Practice of Oncology, 12th ed., Wolters Kluwer, Philadelphia, 2023, 349\u201390."},{"key":"10.1016\/j.phrs.2024.107465_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.mpmed.2020.01.003","article-title":"Management of lung cancer","volume":"48","author":"Coakley","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.phrs.2024.107465_bib44","doi-asserted-by":"crossref","first-page":"931","DOI":"10.37349\/etat.2024.00256","article-title":"A narrative review on perioperative systemic therapy in non-small cell lung cancer","volume":"5","author":"Hsu","year":"2024","journal-title":"Explor Target Antitumor Ther."},{"key":"10.1016\/j.phrs.2024.107465_bib45","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.3390\/jcm13154296","article-title":"Integrative approaches in non-small cell lung cancer management: the role of radiotherapy","volume":"13","author":"Visa","year":"2024","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.phrs.2024.107465_bib46","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1200\/JCO.2017.75.6536","article-title":"Post-treatment mortality after surgery and stereotactic body radiotherapy for early-stage non-small-cell lung cancer","volume":"36","author":"Stokes","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1378\/chest.06-3096","article-title":"Natural history of stage I non-small cell lung cancer: implications for early detection","volume":"132","author":"Raz","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.phrs.2024.107465_bib48","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S1470-2045(21)00401-0","article-title":"Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery","volume":"22","author":"Chang","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00066-013-0450-y","article-title":"Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer","volume":"190","author":"Guckenberger","year":"2014","journal-title":"Strahl. Onkol."},{"key":"10.1016\/j.phrs.2024.107465_bib50","article-title":"A meta-analysis comparing stereotactic body radiotherapy vs conventional radiotherapy in inoperable stage I non-small cell lung cancer","volume":"99","author":"Li","year":"2020","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.phrs.2024.107465_bib51","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2020.11.024","article-title":"Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable stage III NSCLC (PACIFIC)","volume":"151","author":"Faivre-Finn","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.phrs.2024.107465_bib52","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.3390\/jcm13092633","article-title":"A review of the current approach and treatment landscape for stage III non-small cell lung cancer","volume":"13","author":"Sridhar","year":"2024","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.phrs.2024.107465_bib53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.prro.2015.02.012","article-title":"Definitive radiation therapy in locally advanced non-small cell lung cancer: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline","volume":"5","author":"Rodrigues","year":"2015","journal-title":"Pr. Radiat. Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib54","first-page":"1","article-title":"PACIFIC-9: phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer","author":"Barlesi","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib55","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jtho.2019.10.002","article-title":"Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC","volume":"15","author":"Gray","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib56","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib57","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107465_bib58","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.13004","article-title":"Performance status agreement assessed by the patient and clinician in a rapid access lung cancer service: can either predict completion of treatment?","volume":"28","author":"Collins","year":"2019","journal-title":"Eur. J. Cancer Care (Engl.)"},{"key":"10.1016\/j.phrs.2024.107465_bib59","article-title":"Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer","volume":"8","author":"Orillard","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2024.107465_bib60","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cllc.2024.05.002","article-title":"5-Year real-world outcomes with frontline pembrolizumab monotherapy in PD-L1 expression \u2265 50% advanced NSCLC","volume":"25","author":"Velcheti","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.phrs.2024.107465_bib61","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.21037\/tlcr-23-290","article-title":"Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study","volume":"12","author":"G\u00f3mez-Randulfe","year":"2023","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.phrs.2024.107465_bib62","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib63","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.21037\/tcr.2019.12.69","article-title":"Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies","volume":"8","author":"De Giglio","year":"2019","journal-title":"Transl. Cancer Res"},{"key":"10.1016\/j.phrs.2024.107465_bib64","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2024.107465_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114296","article-title":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial","volume":"211","author":"Reck","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"Pt 2","key":"10.1016\/j.phrs.2024.107465_bib66","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.semcancer.2022.03.020","article-title":"The evolutionary legacy of immune checkpoint inhibitors","volume":"86","author":"Kaushik","year":"2022","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.phrs.2024.107465_bib67","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2024.107465_bib68","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jtho.2019.01.016","article-title":"Health-related quality of life in KEYNOTE-010: a Phase II\/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib69","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdy545","article-title":"Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial","volume":"30","author":"Herbst","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib70","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, Phase III trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib71","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejca.2018.11.020","article-title":"Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: results from the randomised phase III OAK study","volume":"107","author":"von Pawel","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2024.107465_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000567","article-title":"Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy","volume":"5","author":"Garon","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.phrs.2024.107465_bib73","series-title":"The MD Anderson Manual of Medical Oncology, fourth ed.","first-page":"535","article-title":"Targeted therapies in non-small cell lung cancer","author":"Elamin","year":"2022"},{"key":"10.1016\/j.phrs.2024.107465_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107465_bib75","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.11.021","article-title":"Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations","volume":"162","author":"Iwama","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2024.107465_bib76","article-title":"Antibody-drug conjugates for lung cancer: payloads and progress","volume":"43","author":"Rosner","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.phrs.2024.107465_bib77","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231175438","article-title":"Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy?","volume":"15","author":"Merkin","year":"2023","journal-title":"Ther. Adv. Med Oncol."},{"issue":"10055","key":"10.1016\/j.phrs.2024.107465_bib78","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","volume":"388","author":"Mulvenna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107465_bib79","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2024.107465_bib80","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.3390\/ijms25084208","article-title":"Transitioning to a personalized approach in molecularly subtyped small-cell lung cancer (SCLC)","volume":"25","author":"Grenda","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2024.107465_bib81","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/JTO.0000000000000142","article-title":"Small-cell lung cancers in patients who never smoked cigarettes","volume":"9","author":"Varghese","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2024.107465_bib82","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2024.107465_bib83","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2024.107465_bib84","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/1097-0142(19810401)47:7<1863::AID-CNCR2820470724>3.0.CO;2-6","article-title":"Small-cell carcinoma of the lung--survival according to histologic subtype: a Veterans Administration Lung Group Study","volume":"47","author":"Davis","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2024.107465_bib85","unstructured":"Hann C.L., Drapkin B.J., Wu A.J., Rekhtman N. Minna J.D. Small cell and neuroendocrine tumors of the lung. in DeVita VT Jr, Lawrence TS, Rosenberg SA (Eds.), Cancer Principles and Practice of Oncology, 12th ed., Wolters Kluwer, Philadelphia, 2023, 391\u2013422."},{"key":"10.1016\/j.phrs.2024.107465_bib86","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","article-title":"Tarlatamab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2024.107465_bib87","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40265-021-01508-y","article-title":"Trilaciclib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824004109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824004109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T19:57:31Z","timestamp":1731009451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824004109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":87,"alternative-id":["S1043661824004109"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107465","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted and cytotoxic inhibitors used in the treatment of lung cancers","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107465"}}